{"organizations": [], "uuid": "47ae2e308f9693d6573c373a75aa7fb31485a07b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/bayer-results/bayer-q4-profit-edges-lower-as-crop-chems-consumer-care-weigh-idUSF9N1QB00L", "country": "US", "domain_rank": 408, "title": "Bayer Q4 profit edges lower as crop chems, consumer care weigh", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T14:46:00.000+02:00", "replies_count": 0, "uuid": "47ae2e308f9693d6573c373a75aa7fb31485a07b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/bayer-results/bayer-q4-profit-edges-lower-as-crop-chems-consumer-care-weigh-idUSF9N1QB00L", "ord_in_thread": 0, "title": "Bayer Q4 profit edges lower as crop chems, consumer care weigh", "locations": [], "entities": {"persons": [{"name": "maria sheahan", "sentiment": "none"}], "locations": [{"name": "germany", "sentiment": "none"}, {"name": "brazil", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "bayer", "sentiment": "negative"}, {"name": "leverkusen", "sentiment": "negative"}, {"name": "ludwig burger editing", "sentiment": "none"}, {"name": "ebitda", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LEVERKUSEN, Germany, Feb 28 (Reuters) - German drugmaker Bayer’s adjusted core earnings slipped 1.3 percent in the fourth quarter, as it tries to overcome weak demand for crop protection products in Brazil and a drop in sales of consumer care products.\nBayer’s adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at 1.78 billion euros ($2.18 billion) for the quarter, slightly lower than the average forecast by analysts of 1.8 billion euros.\nIt said 2018 adjusted EBITDA would be at the prior-year level, held back by a burden of about 300 million euros from a warning letter by the U.S. Food and Drug Administration. ($1 = 0.8177 euros) (Reporting by Ludwig Burger Editing by Maria Sheahan)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T14:46:00.000+02:00", "crawled": "2018-02-28T10:02:04.000+02:00", "highlightTitle": ""}